NCT01351805 2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA Completed
Clinical Trials
37 trialsNCT03649061 2025-06-19
CareRA2020
Universitaire Ziekenhuizen KU Leuven
Phase 4 Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT02760433 2023-09-21
CREDO 3
R-Pharm
Phase 3 Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT02538341 2021-11-23
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
University of Alabama at Birmingham
Phase 2 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01548768 2020-11-27
RHYTHM
Columbia University
Phase 4 Completed
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT01721044 2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3 Completed
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT00503425 2017-08-15
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Hoffmann-La Roche
Phase 3 Completed
NCT01362062 2017-08-02
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hoffmann-La Roche
Completed
NCT01351480 2017-03-13
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
Arthritis & Rheumatic Disease Specialties Research
Phase 3 Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT01715896 2016-10-31
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
MedImmune LLC
Phase 2 Completed
NCT00468546 2016-10-25
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT01613027 2016-10-24
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
Hoffmann-La Roche
Completed
NCT01641952 2016-08-17
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
Hoffmann-La Roche
Completed
NCT01309282 2016-08-12
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Hoffmann-La Roche
Completed
NCT02519387 2016-07-20
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
Mundipharma Pharmaceuticals Sdn. Bhd.
Phase 4 Completed
NCT01350804 2016-05-23
NURTURE 1
Novartis
Phase 3 Completed
NCT00651625 2016-03-02
RPD
University of New Mexico
Phase NA Completed
NCT01069419 2015-10-29
FasT
UCB Pharma
Completed
NCT00883753 2014-08-06
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT00361335 2014-07-29
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc.
Phase 3 Completed
NCT01374971 2014-04-08
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
Arthritis Treatment Center, Maryland
Phase 3 Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT00427804 2013-02-04
Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption
Atlanta VA Medical Center
Phase NA Completed
NCT00048581 2011-11-21
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Bristol-Myers Squibb
Phase 3 Completed
NCT01078571 2011-10-28
DALI
Abbott
Completed